AI-backed imaging and care coordination firm Viz.ai is partnering with biotechnology firm Regeneron and biopharmaceutical firm Sanofi to deploy and examine an AI-enabled workflow device for COPD.
Viz.ai presents a care coordination platform with greater than 50 FDA-cleared algorithms that assist analyze medical imaging information to offer insights into prognosis, streamline workflows and help with remedy choices.
The corporate presents AI-enabled neurology, trauma, cardiology, radiology and vascular care instruments.
By means of the partnership, Sanofi and Regeneron will help the corporate’s investigation of its Viz COPD Module, which employs AI and digital well being document information, utilizing pure language processing to detect and handle high-risk COPD sufferers.
COPD is a standard lung illness that causes harm to the lungs and can lead to restricted airflow and respiratory issues.
“At Sanofi, we’re excited to collaborate with Viz.ai to additional tackle unmet wants in COPD care by leveraging AI,” Dr. Paul Rowe, ATSF and head of medical and specialty care at Sanofi, mentioned in an announcement.
“With this collaboration, we’ll examine the influence of the Viz COPD module, a streamlined AI-enabled EHR workflow to enhance entry to care and finally affected person outcomes in COPD, a illness that continues to be under-prioritized, underfunded and undertreated compared to different noncommunicable ailments.”
THE LARGER TREND
Earlier this 12 months, Viz.ai introduced a collaboration with oncology-focused biotech firm Guardant Health to make use of AI and genomics to deal with challenges in lung most cancers care.
In 2024, Viz.ai introduced a collaboration with Microsoft to supply its AI fashions via the tech big’s Precision Imaging Community, a part of Microsoft Cloud for Healthcare. The partnership, geared toward bettering scientific workflows for radiologists, noticed greater than 48 AI fashions built-in into Microsoft’s platform.
The corporate additionally introduced quite a few different collaborations, together with alliances with coronary heart assault prediction startup Cleerly and the Addario Lung Most cancers Medical Institute, a nonprofit group that performs lung most cancers analysis.
In 2023, Viz.ai signed a multiyear agreement with international pharmaceutical firm Bristol Myers Squibb to launch an AI-enabled algorithm and software program for supplier workflow dubbed Viz HCM.
In 2022, Viz.ai secured $100 million in Series D funding, bringing its valuation to $1.2 billion. The funding got here one 12 months after the corporate closed its Series C funding round worth $71 million.
Trending Merchandise
